CD20 negative

This case highlights the diagnostic limitation of endoscopic biopsy following rituximab therapy. Therefore, clinicians should be cautious in relying solely on endoscopic findings and remain open to surgical intervention to achieve a timely and accurate diagnosis.

P=N/A, N=44, Not yet recruiting, National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College; National Cancer Center / Cancer Hospit

In contrast, recent studies have shown that TdT-positive DLBCL/HGBCL-MYC/BCL2 and B-ALL with MYC rearrangement have distinct molecular features. In conclusion, an analysis of 93 cases, including our four cases, suggests that MYC rearrangement contributes to immature immunophenotypic profiles in both lymphoma and leukemia, emphasizing the importance of a refined classification that integrates morphology, immunophenotype, and genetics.

P3, N=306, Active, not recruiting, GWT-TUD GmbH | Trial primary completion date: Dec 2026 --> Dec 2025 | Trial completion date: Dec 2027 --> Dec 2025

P1/2, N=95, Active, not recruiting, Kite, A Gilead Company | Trial primary completion date: Sep 2024 --> Feb 2026

P1/2, N=33, Active, not recruiting, Han weidong | Recruiting --> Active, not recruiting | Trial completion date: Dec 2025 --> Sep 2026 | Trial primary completion date: Dec 2024 --> May 2025

Despite multiple lines of systemic therapy, including R-CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone combined with rituximab), methotrexate, gemcitabine, platinum-based chemotherapy, and autologous stem cell transplant, the disease progressed, ultimately leading to the patient's death. This case highlights an atypical clinical presentation of PCDLBCL-LT in a young male, initially mimicking T-cell lymphoma. The diagnostic evolution underscores the importance of repeated biopsies and immunohistochemical reevaluation in persistent or atypical cutaneous lymphoproliferative disorders. It also raises awareness of CD20-negative variants and potential coexistence with T-cell lymphomas such as mycosis fungoides.

P2, N=190, Recruiting, Pierre Fabre Medicament | Trial completion date: May 2029 --> May 2028

CD20 expression in the HRS cells of CHL patients was not significantly associated with clinical outcomes. Further studies with larger patient populations and extended follow-up periods are required to validate these findings.

Common features of these aggressive tumors are high-grade histology with immunoblastic or plasmablastic differentiation, the absence or weak expression of mature B-cell markers such as CD20 and the frequent expression of plasma cell-associated markers. The aim of this review is to highlight the diagnostic challenges associated with the group of CD20-negative aggressive B-cell lymphomas, emphasizing key morphologic and molecular features, which are critical in the diagnosis of the different entities belonging to this rare group of diseases.

P1, N=18, Active, not recruiting, Dana-Farber Cancer Institute | Trial completion date: Jun 2025 --> Jun 2038

P1/2, N=52, Terminated, Autolus Limited | Completed --> Terminated; After reviewing the data and taking into consideration the available treatment landscape in r/r DLBCL, Autolus didn't progress into the Phase II part of the study and submitted a Notification of End of Trial (MHRA reference 46113/0003/001-0016).